Dotatate gallium Ga-68

Summary

Gallium Ga-68 dotatate (Netspot) is an FDA-approved PET imaging agent used for the localization of somatostatin receptor-positive neuroendocrine tumors (NETs) in adults and pediatric patients (≥2 years). It consists of the somatostatin analogue DOTA-Tyr3-octreotate chelated to the radiometal gallium-68 and provides superior sensitivity and resolution compared to conventional somatostatin receptor scintigraphy (octreotide scan).

Mechanism of Action

Dotatate (DOTA-Tyr3-octreotate) is a somatostatin analogue that binds with high affinity to somatostatin receptor subtype 2 (SSTR2), which is overexpressed on neuroendocrine tumor cells. When labeled with gallium-68 (a positron-emitting radionuclide), the conjugate enables positron emission tomography (PET) imaging of SSTR2-expressing tumors by localizing to tumor tissue and emitting positrons detectable by PET scanner.

Routes of Administration

Goals & Uses

• Staging and restaging of NETsDiagnostic OncologyHigh
• Localization of somatostatin receptor-positive neuroendocrine tumorsDiagnostic ImagingHigh
• Monitoring response to somatostatin analogue therapyTreatment MonitoringModerate
• Detection of occult primary NETDiagnostic ImagingModerate
• Patient selection for PRRT (peptide receptor radionuclide therapy)Treatment PlanningHigh

Contraindications

• PregnancyPopulationHighPotential fetal risk or insufficient safety data
• BreastfeedingPopulationModeratePotential transfer into breast milk or insufficient safety data
• Hypersensitivity to dotatate or any component of the formulationAllergyHigh

Adverse Effects

• Radiation exposureRadiologicalCommon
• Hypersensitivity/anaphylaxisImmunologicalRare
• Injection site pain/irritationLocalUncommon
• FlushingVascularUncommonWarmth and redness of the skin
• NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit

Drug Interactions

• Long-acting somatostatin analogues (e.g., octreotide LAR, lanreotide)Moderate
• Short-acting octreotideLow

Population Constraints

• Renal impairmentOrgan ImpairmentRelative
• Pregnant womenReproductiveRelative
• Pediatric patients <2 yearsAgeRelative

Regulatory Status

• European UnionApprovedApproved: PET imaging of somatostatin receptor-positive neuroendocrine tumors in adultsApproved by EMA; marketed as SomaKit TOC in some European markets by AAA/Novartis.
• United StatesApprovedApproved: PET imaging for localization of somatostatin receptor-positive neuroendocrine tumors (NETs) in adults and pediatric patients ≥2 yearsApproved June 1, 2016. NDA 208547. Brand: Netspot. Sponsor: Advanced Accelerator Applications USA, Inc. (Novartis). Orphan drug designation for NETs.
• United KingdomApprovedApproved: PET imaging of somatostatin receptor-positive neuroendocrine tumorsRecognized under MHRA framework post-Brexit; widely used in NHS specialized centers.

FDA approved in June 2016 (NDA 208547) under the brand name Netspot. Also approved in the EU. Indicated for PET imaging of SSTR-positive NETs. Classified as a radioactive drug requiring handling per radiation safety guidelines.

Evidence & Sources

No sources recorded yet.